1. Methods, Manners, and the Responsible Conduct of Research
2. Ethics and the Scientist
3. Mentoring
4. Authorship and Peer Review
5. Use of Humans in Biomedical Experimentation
6. Use of Animals in Biomedical Experimentation
7. Competing Interests in Research
8. Collaborative Research
9. Research Data and Intellectual Property
10. Scientific Record Keeping
11. Science, Technology, and Society
Appendix I: Surveys as a Tool for Training in Scientific Integrity
Appendix II: Student Exercises
Appendix III: Standards of Conduct
Appendix IV: Sample Protocols for Human and Animal Experimentation
Appendix V: Example of a U.S. Patent Specification
Appendix VI: Laboratory Notebook Instructions
Appendix VII: Safe Laboratory Practices Resources
Index
Scientific Integrity: Text and Cases in Responsible Conduct of
Research, 4th Edition
Francis L. Macrina, 2014, 530 pages, ASM Press, $52.99
Review by Norman M. Goldfarb is chairman of MAGI and chief
collaboration officer of WCG Clinical. Contact him at
1.650.465.0119 or ngoldfarb@magiworld.org Scientific Integrity:
Text and Cases in Responsible Conduct of Research, 4th Edition
should be required reading for anyone conducting or managing a
clinical research. Clinical research ethics and regulatory
compliance primarily deal with the impacts of clinical studies on
others, principally the protection of study participants, the
generation of high-quality data for study sponsors, and correct
billing to government agencies. Scientific integrity is the
foundation of the responsible conduct of scientific research. In
addition to impacts mentioned above, it also deals with the
scientific research process itself and its impact on researchers.
Scientific integrity is based on the following core values, as
described in the book: Honesty. This applies to all aspects of the
research process, including proposing, performing, reviewing and
reporting research. It requires that conduct across these areas be
free from fraud and deception. Honesty requires being responsible
for one's actions, being truthful, and being obligated to meet any
and all commitments to the research process and to others. Trust.
This value reflects confidence in the research across a spectrum
that covers investigator conduct, methods used, data analysis,
interpretation and reporting. Trust is earned at the level of both
the individual scientist and the institution by the conduct of
research that is lawful and compliant with applicable policies,
regulations and guidelines. Fairness. This value reflects behavior
characterized by sound and impartial judgment. Being fair as a
scientist includes providing appropriate credit to the work of
others, citing the literature accurately and responsibly, providing
appropriate recommendations, conducting objective peer review, and
sharing data. Openness. Openness is characterized by forthright
discussion with and accessibility to the scientific community and
to the public. It applies to individual scientist's conduct,
conflict disclosure and management, communication with the
scientific and public communities, reporting of research results,
and acknowledgment of research contributions. Accountability.
Scientists are required to be accountable for and are answerable
for their actions in proposing, performing, reviewing and reporting
research. Stewardship. This is expressed in a variety of ways to
include efficient and non-wasteful use of resources, responsible
use of research funds, duty of care in conducting research that
involves human or animal subjects, and responsibility for the
training and preparation of future generations of scientists.
Objectivity. Objectivity requires that interpretations be based on
facts and evidence that have been properly collected and rigorously
analyzed, and that conclusions are free of improper bias. Accuracy
and reliability. These values involve exercising care to avoid
errors in the performance of research and precise reporting and
communicating of the research process, the results, and the
conclusions. Impartiality and independence. Scientists establish
their impartiality by being proactive in the identification of
conflicts of interest, and then by disclosing and reporting them as
appropriate to their institutions, sponsors and the scientific
publication and review enterprise. Where necessary, scientists work
with the appropriate bodies to create and implement management
plans to reduce or eliminate perceived or real conflicts. This
process affirms the scientist's independence in his or her
proposing, conducting, reporting or reviewing research by
insulating their work from the inappropriate connection to outside
interested parties, from ideological or political pressure groups,
and from economic interests that might lead to bias in judgment.
The book includes dozens of cases for discussion, such as the
following two: Dr. Colleen May is a participating neurologist in a
clinical trial to assess the efficacy and toxicity of a new
anticonvulsant medication. For the duration of the 2-year study,
each neurologist is to meet with each of his or her patients for an
average of 30 minutes each month. In Dr. May's case, this amounts
to an average of 20 hours per month. During each visit, the
physicians administer a variety of specialized tests, requiring
judgments dependent on their experience and training in neurology.
At the completion of the study, the results are to be unblinded and
analyzed by the project leaders. It is anticipated that at least
two publications will be prepared for the New England Journal of
Medicine. Dr. May has just learned that she will be listed in the
acknowledgments but not as a coauthor of the manuscript. Dr. May
argues that she has provided nearly 500 hours of her expert time,
far more than needed to complete a publishable study in her
experimental laboratory. Does Dr. May have a case for authorship?
Why or why not? A proposal currently under consideration by your
IRB involves the administration of fluorescently labeled,
mouse-derived monoclonal antibodies to patients. These immunologic
reagents would be used to test their ability to localize and
diagnose tumors. The committee discusses the informed consent form
proposed for use in these experiments. Specifically, one member of
the committee argues that the consent form fails reveal that
participation in this study could preclude the future use of
anti-tumor, mouse-derived monoclonal antibody therapy in these
patients. This argument is based on the possibility that such
patients could mount an anti-mouse antibody response. Considerable
disagreement among committee members erupts as a result of this
issue. Where do you stand? Why? The book includes 11 chapters by
seven contributors: Methods, Manners, and the Responsible Conduct
of ResearchEthics and the ScientistMentoringAuthorship and Peer
ReviewUse of Humans in Biomedical ExperimentationUse of Animals in
Biomedical ExperimentationCompeting Interests in
ResearchCollaborative ResearchResearch Data and Intellectual
PropertyScientific Record KeepingScience, Technology and Society
![]() |
Ask a Question About this Product More... |
![]() |